ArticleInternational urology and nephrology2026
Integrated single-cell analysis identifies a ferroptosis-resistant tumor microenvironment subset in renal cell carcinoma.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeThis study aimed to characterize ferroptosis heterogeneity within the tumor microenvironment (TME) of clear cell renal cell carcinoma (ccRCC) and investigate its impact on immune remodeling and clinical prognosis.
methodsSingle-cell transcriptomic analysis was performed using the GSE159115 dataset to classify cell phenotypes. Functional enrichment, immune infiltration, and pathway analyses (GSEA) were conducted. Validation utilized the GSE312695 and TCGA-KIRC cohorts.
resultsccRCC tissues were enriched with ferroptosis-resistant cells, whereas normal tissues contained ferroptosis-sensitive cells. Eight core genes regulating ferroptosis susceptibility were identified. Resistant cells established an immunosuppressive "immune desert" TME, with significant suppression of T-cell and macrophage pathways. The ferroptosis resistance signature demonstrated generalizability across cohorts, and medium-high resistance scores showed a trend toward poorer survival in specific subgroups, although overall survival differences did not reach statistical significance.
conclusionFerroptosis heterogeneity contributes to ccRCC progression by shaping an immunosuppressive TME. The identified molecular features offer potential targets for therapy and highlight the complexity of utilizing ferroptosis signatures for prognostic assessment in ccRCC.
Indexed as
Identifiers
42430097What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.